Fig 1.
Kinetics of the serum PTH level according to the patient group.
*: p< 0.05 with previous month. Mean ± SEM.
Fig 2.
Kinetics of the serum calcium level according to the patient group.
*: p< 0.05 with previous month. Mean ± SEM.
Fig 3.
Kinetics of the serum phosphate level according to the patient group.
*: p<0.05 with previous month. Mean ± SEM.
Fig 4.
Kinetics of the serum b-ALP level from baseline according to the patient group.
Mean ± SEM.
Fig 5.
Kinetics of the serum CTX level from baseline according to the patient group.
Mean ± SEM. *: p<0.05 = difference with previous value.
Table 1.
Baseline characteristics of the patients stratified according to a future severe SHPT occurring during the study period.
Mean ± SD except for serum CRP and PTH: Median (IQR).
Table 2.
Logistic regression analysis of the baseline factors which were associated with the risk of developing severe SHPT.
Age, diabetes, cardiac disease, cancer, phosphataemia and sevelamer use were not significantly associated with the risk for severe SHPT.
Table 3.
Evolution of treatments for SHPT according to the patient group.
Fig 6.
Relative risk of future severe SHPT according to the baseline CTX or / and PTH values.
High CTX: > 1.2 μg/L; high PTH: > 374 pg/ml. ** p< 0.001; *** p< 0.0001.